Shares of Verona Pharma Plc (LON:VRP) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $54.90 and traded as low as $48.00. Verona Pharma shares last traded at $48.50, with a volume of 21,320 shares traded.
Separately, Shore Capital reaffirmed a “buy” rating on shares of Verona Pharma in a report on Monday, August 5th.
The company has a market capitalization of $51.08 million and a P/E ratio of -2.59. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.95 and a quick ratio of 5.60. The company has a fifty day moving average price of GBX 45.86 and a two-hundred day moving average price of GBX 54.90.
In related news, insider David Ebsworth bought 60,000 shares of the stock in a transaction that occurred on Thursday, August 8th. The stock was acquired at an average cost of GBX 50 ($0.65) per share, with a total value of £30,000 ($39,200.31).
Verona Pharma Company Profile (LON:VRP)
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis.
Recommended Story: Stocks Increasing Dividends
Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.